Assertio Holdings Inc
ASRT
查看详细走势图
0.720USD
+0.008+1.15%
收盘 12/19, 16:00（美东）报价延迟15分钟
69.30M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.15%
5天
-5.50%
1月
+0.11%
6月
+14.43%
今年开始到现在
-17.35%
1年
-18.73%
查看详细走势图
TradingKey Assertio Holdings Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Assertio Holdings Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名105/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价2.66。中期看，股价处于下降通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Assertio Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
买入
评级
2.663
目标均价
+241.21%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Assertio Holdings Inc亮点
亮点风险
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
估值低估
公司最新PE估值-2.38，处于3年历史低位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值4.43M
Assertio Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Assertio Holdings Inc简介
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
公司代码ASRT
公司Assertio Holdings Inc
CEOReisenauer (Mark L)
网址https://www.assertiotx.com/
常见问题
Assertio Holdings Inc(ASRT)的当前股价是多少？
Assertio Holdings Inc(ASRT)的当前股价是 0.720。
Assertio Holdings Inc的股票代码是什么？
Assertio Holdings Inc的股票代码是ASRT。
Assertio Holdings Inc股票的52周最高点是多少？
Assertio Holdings Inc股票的52周最高点是1.010。
Assertio Holdings Inc股票的52周最低点是多少？
Assertio Holdings Inc股票的52周最低点是0.514。
Assertio Holdings Inc的市值是多少？
Assertio Holdings Inc的市值是69.30M。
Assertio Holdings Inc的净利润是多少？
Assertio Holdings Inc的净利润为-21.58M。
现在Assertio Holdings Inc(ASRT)的股票是买入、持有还是卖出？
根据分析师评级，Assertio Holdings Inc(ASRT)的总体评级为买入，目标价格为2.663。
Assertio Holdings Inc(ASRT)股票的每股收益（EPS TTM）是多少
Assertio Holdings Inc(ASRT)股票的每股收益（EPS TTM）是-0.302。
相关品种
